CL · Colgate Palmolive Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.32B | - | $5.13B | $5.11B | $4.91B | - | $5.03B | $5.06B | $5.07B | - |
| Cost of Revenue | $2.10B | - | $2.08B | $2.04B | $1.92B | - | $1.96B | $1.99B | $2.03B | - |
| Gross Profit | $3.23B | - | $3.05B | $3.07B | $2.99B | - | $3.07B | $3.07B | $3.04B | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $2.08B | - | $1.97B | $1.96B | $1.90B | - | $1.98B | $1.94B | $1.92B | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $156.00M | - | $150.00M | $157.00M | $148.00M | - | - | - | $150.00M | - |
| Operating Income | $964.00M | - | $1.06B | $1.08B | $1.08B | - | $1.06B | $1.09B | $1.05B | - |
| Interest Expense | $62.00M | - | $67.00M | $71.00M | $73.00M | - | - | - | - | - |
| Income Tax | $211.00M | - | $226.00M | $234.00M | $227.00M | - | $210.00M | $243.00M | $238.00M | - |
| Net Income | $646.00M | - | $735.00M | $743.00M | $690.00M | - | $737.00M | $731.00M | $683.00M | - |
| EPS - Basic | $0.81 | - | $0.91 | $0.92 | $0.85 | - | $0.90 | $0.89 | $0.83 | - |
| EPS - Diluted | $0.80 | - | $0.91 | $0.91 | $0.85 | - | $0.90 | $0.89 | $0.83 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.33B | $1.29B | $1.28B | $1.22B | $1.11B | $1.10B | $1.23B | $1.11B | $1.08B | $966.00M |
| Accounts Receivable | $1.89B | $1.68B | $1.81B | $1.77B | $1.73B | $1.52B | $1.71B | $1.82B | $1.81B | $1.59B |
| Inventory | $2.09B | $2.03B | $2.11B | $2.12B | $2.13B | $1.99B | $2.04B | $1.92B | $1.91B | $1.93B |
| Accounts Payable | $2.10B | $2.09B | $1.87B | $1.79B | $1.80B | $1.80B | $1.63B | $1.56B | $1.65B | $1.70B |
| Current Assets | $6.08B | $5.71B | $6.04B | $6.00B | $5.81B | $5.32B | $5.81B | $5.65B | $5.64B | $5.28B |
| Total Assets | $16.61B | $16.33B | $17.51B | $17.47B | $16.65B | $16.05B | $16.77B | $16.48B | $16.57B | $16.39B |
| Current Liabilities | $5.93B | $6.85B | $6.50B | $6.78B | $6.86B | $5.76B | $5.57B | $5.35B | $5.31B | $4.74B |
| Long-term Debt | $7.94B | $6.87B | $7.31B | $7.14B | $6.57B | $7.29B | $7.91B | $8.15B | $8.15B | $8.22B |
| Total Liabilities | $16.12B | $15.96B | $16.27B | $16.42B | $15.91B | $15.50B | $15.94B | $16.00B | $15.95B | $15.44B |
| Stockholders' Equity | $145.00M | $54.00M | $856.00M | $702.00M | $363.00M | $212.00M | $435.00M | $123.00M | $230.00M | $609.00M |
| Retained Earnings | $26.82B | $26.59B | $27.05B | $26.73B | $26.41B | $26.14B | $25.81B | $25.49B | $25.16B | $25.29B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $747.00M | - | - | - | $600.00M | - | - | - | $681.00M | - |
| Investing Cash Flow | ($122.00M) | - | - | - | ($159.00M) | - | - | - | ($193.00M) | - |
| Financing Cash Flow | ($563.00M) | - | - | - | ($458.00M) | - | - | - | ($361.00M) | - |
| CapEx | $138.00M | - | - | - | $124.00M | - | - | - | $126.00M | - |
| Free Cash Flow | $609.00M | - | - | - | $476.00M | - | - | - | $555.00M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 60.6% | - | 59.4% | 60.1% | 60.8% | - | 61.1% | 60.6% | 60.0% | - |
| Operating margin | 18.1% | - | 20.6% | 21.1% | 21.9% | - | 21.2% | 21.6% | 20.7% | - |
| EBITDA margin | 21.0% | - | 23.6% | 24.2% | 24.9% | - | - | - | 23.6% | - |
| Net margin | 12.1% | - | 14.3% | 14.5% | 14.1% | - | 14.6% | 14.5% | 13.5% | - |
| Free cash flow margin | 11.4% | - | - | - | 9.7% | - | - | - | 11.0% | - |
| FCF / Net income | 0.94 | - | - | - | 0.69 | - | - | - | 0.81 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 39.0% | - | 38.4% | 38.4% | 38.6% | - | 39.3% | 38.3% | 37.8% | - |
| Effective tax rate | 24.6% | - | 23.5% | 24.0% | 24.8% | - | 22.2% | 24.9% | 25.8% | - |
| Return on assets | 3.9% | - | 4.2% | 4.3% | 4.1% | - | 4.4% | 4.4% | 4.1% | - |
| Return on equity | 445.5% | - | 85.9% | 105.8% | 190.1% | - | 169.4% | 594.3% | 297.0% | - |
| Return on invested capital | 9.0% | - | 9.9% | 10.5% | 11.7% | - | 9.9% | 9.9% | 9.3% | - |
| Liquidity | ||||||||||
| Current ratio | 1.02 | 0.83 | 0.93 | 0.89 | 0.85 | 0.92 | 1.04 | 1.06 | 1.06 | 1.11 |
| Quick ratio | 0.67 | 0.54 | 0.60 | 0.57 | 0.54 | 0.58 | 0.68 | 0.70 | 0.70 | 0.71 |
| Cash ratio | 0.22 | 0.19 | 0.20 | 0.18 | 0.16 | 0.19 | 0.22 | 0.21 | 0.20 | 0.20 |
| Leverage | ||||||||||
| Debt / Equity | 54.74 | 127.24 | 8.54 | 10.18 | 18.10 | 34.38 | 18.18 | 66.23 | 35.44 | 13.50 |
| Debt / Assets | 0.48 | 0.42 | 0.42 | 0.41 | 0.39 | 0.45 | 0.47 | 0.49 | 0.49 | 0.50 |
| Debt / EBITDA | 7.09 | - | 6.04 | 5.78 | 5.37 | - | - | - | 6.81 | - |
| Interest coverage | 15.5x | - | 15.8x | 15.2x | 14.7x | - | - | - | - | - |
| Equity multiplier | 114.55 | 302.41 | 20.46 | 24.89 | 45.86 | 75.69 | 38.56 | 133.98 | 72.05 | 26.92 |
| Liabilities / Assets | 0.97 | 0.98 | 0.93 | 0.94 | 0.96 | 0.97 | 0.95 | 0.97 | 0.96 | 0.94 |
| Efficiency | ||||||||||
| Asset turnover | 0.32 | - | 0.29 | 0.29 | 0.30 | - | 0.30 | 0.31 | 0.31 | - |
| Inventory turnover | 1.01 | - | 0.99 | 0.96 | 0.91 | - | 0.96 | 1.04 | 1.06 | - |
| Days sales outstanding | 130d | - | 129d | 127d | 128d | - | 124d | 132d | 131d | - |
| Days inventory outstanding | 363d | - | 370d | 379d | 403d | - | 380d | 352d | 345d | - |
| Days payable outstanding | 365d | - | 327d | 320d | 341d | - | 303d | 285d | 297d | - |
| Cash conversion cycle | 128d | - | 171d | 186d | 190d | - | 202d | 199d | 179d | - |
| Valuation | ||||||||||
| P / E | 106.5x | - | 87.8x | 99.9x | 110.2x | - | 115.3x | 109.0x | 108.5x | - |
| P / B | 473.2x | - | 75.7x | 105.3x | 210.4x | - | 196.3x | 649.9x | 323.4x | - |
| P / S | 12.9x | - | 12.6x | 14.5x | 15.5x | - | 17.0x | 15.8x | 14.7x | - |
| EV / EBITDA | 67.2x | - | 58.6x | 64.6x | 66.9x | - | - | - | 68.0x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 8.4% | - | 1.9% | 1.0% | -3.0% | - | 2.4% | 4.9% | 6.2% | - |
| Revenue CAGR (3y) | 3.7% | - | 4.8% | 4.5% | 3.7% | - | 4.5% | 5.9% | 5.3% | - |
| Revenue CAGR (5y) | 4.2% | - | 4.3% | 5.6% | 3.7% | - | 5.1% | 5.5% | 5.5% | - |
| Gross profit growth (YoY) | 8.0% | - | -0.8% | 0.1% | -1.7% | - | 6.8% | 10.0% | 12.1% | - |
| Operating income growth (YoY) | -10.4% | - | -0.6% | -1.1% | 2.8% | - | 3.5% | 12.1% | 15.2% | - |
| Net income growth (YoY) | -6.4% | - | -0.3% | 1.6% | 1.0% | - | 4.1% | 45.6% | 83.6% | - |
| EPS growth (YoY) | -5.9% | - | 1.1% | 2.2% | 2.4% | - | 4.7% | 48.3% | 84.4% | - |
| EPS CAGR (3y) | 21.1% | - | 7.1% | 8.1% | 8.8% | - | 6.3% | 2.4% | 1.2% | - |
| EPS CAGR (5y) | 0.0% | - | 2.4% | 4.2% | 0.5% | - | 6.1% | 5.5% | 5.0% | - |
| FCF growth (YoY) | 27.9% | - | - | - | -14.2% | - | - | - | -3.0% | - |
| FCF CAGR (5y) | 4.4% | - | - | - | -7.0% | - | - | - | 0.8% | - |
| Book value growth (YoY) | -60.1% | -74.5% | 96.8% | 470.7% | 57.8% | -65.2% | - | - | - | 51.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$20.38B totalOral Personal And Home Care$15.77B · 77.4%
Pet Nutrition$4.61B · 22.6%
Geographic
$19.36B totalLatin America$4.78B · 24.7%
North America$4.04B · 20.9%
US$3.60B · 18.6%
Europe$2.96B · 15.3%
Asia Pacific$2.81B · 14.5%
Africa Eurasia$1.17B · 6.1%
Peer comparison
Same SIC group: Perfumes, Cosmetics & Other Toilet Preparations
Comparing COLGATE PALMOLIVE CO against the 5 most active filers in the same SIC group.
Dividends
$2.09/share trailing 12 months · +3.5% YoY
| Ex-date | Per share |
|---|---|
| Apr 20, 2026 | $0.5300 |
| Jan 21, 2026 | $0.5200 |
| Oct 17, 2025 | $0.5200 |
| Jul 18, 2025 | $0.5200 |
| Apr 17, 2025 | $0.5200 |
| Jan 21, 2025 | $0.5000 |
| Oct 18, 2024 | $0.5000 |
| Jul 19, 2024 | $0.5000 |
| Apr 19, 2024 | $0.5000 |
| Jan 19, 2024 | $0.4800 |
| Oct 20, 2023 | $0.4800 |
| Jul 20, 2023 | $0.4800 |
| Apr 20, 2023 | $0.4800 |
| Jan 20, 2023 | $0.4700 |
| Oct 20, 2022 | $0.4700 |
| Jul 20, 2022 | $0.4700 |
| Apr 20, 2022 | $0.4700 |
| Jan 21, 2022 | $0.4500 |
| Oct 20, 2021 | $0.4500 |
| Jul 20, 2021 | $0.4500 |
| Apr 20, 2021 | $0.4500 |
| Jan 22, 2021 | $0.4400 |
| Oct 22, 2020 | $0.4400 |
| Jul 17, 2020 | $0.4400 |